Refining the Role for Adjuvant Radiotherapy in Gastric Cancer: Risk Stratification Is Key
Mené sur 458 patients atteints d'un cancer de l'estomac et ayant subi entre 2004 et 2008 une gastrectomie avec curage ganglionnaire D2 (durée de suivi : 7 ans), cet essai de phase III évalue l'intérêt d'ajouter une radiothérapie à une chimiothérapie adjuvante par capécitabine et cisplatine pour améliorer la survie sans maladie et la survie globale des patients
Adjuvant therapy for gastric cancer has been investigated in successive clinical trials over the last four decades, ultimately leading us closer to more effective and risk-stratified therapies after gastric resection. The international efforts to improve outcomes for gastric cancer and to define the appropriate adjuvant regimen are a testament to the global impact of this disease, with approximately one million patients diagnosed per year and almost 750,000 deaths annually worldwide.The final report of the Adjuvant Chemoradiotherapy Trial in Stomach Tumors (ARTIST) trial accompanying this editorial presents updated analyses that may help us to better tailor adjuvant therapies after gastric resection.
Journal of Clinical Oncology , éditorial en libre accès, 2015